| 2026-09-14 | 8-K | 10.1 | Separation Agreement and General Release of Claims, dated as of September 8, 2026, between Quince Therapeutics, Inc. and Charles Ryan. |
|---|
| 2026-08-14 | 10-Q | 10.7 | License and Supply Agreement, dated May 14, 2026, by and between Plastiape S.p.A. and Orphai Therapeutics, Inc. |
|---|
| 2026-05-18 | 8-K | 10.6 | Retention Bonus Agreement dated May 17, 2026 between the Company and Brendan Hannah |
|---|
| 2026-05-18 | 8-K | 10.5 | Retention Bonus Agreement dated May 17, 2026 between the Company and Dirk Thye |
|---|
| 2026-05-18 | 8-K | 10.4 | Employment Letter between Orphai Therapeutics Inc. and Brigette Roberts, effective May 12, 2026. |
|---|
| 2026-05-18 | 8-K | 10.3 | Employment Letter between the Company and Brigette Roberts, effective May 18, 2026 |
|---|
| 2026-05-18 | 8-K | 10.2 | Form of Registration Rights Agreement, by and among Quince Therapeutics, Inc. and certain investors signatory thereto |
|---|
| 2026-05-18 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated as of May 18, 2026, by and among Quince Therapeutics, Inc. and each investor listed on Exhibit A thereto |
|---|
| 2025-11-12 | 10-Q | 10.1 | Amendment to Accession, Amendment, and Restatement Agreement to the Finance Contract dated September 25, 2025 by and between Quince Therapeutics, Inc., EryDel Italy, Inc., EryDel US, Inc., EryDel USA, Inc., EryDel S.p.A., and the European Investment Bank |
|---|
| 2025-06-13 | 8-K | 10.2 | Form of Registration Rights Agreement, dated June 12, 2025, by and among Quince Therapeutics, Inc. and each of the several purchasers signatory thereto. |
|---|
| 2025-06-13 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated June 12, 2025, by and among Quince Therapeutics, Inc. and each of the several purchasers signatory thereto. |
|---|
| 2025-03-24 | 10-K | 10.15 | Outside Director Compensation Policy adopted April 9,2019; Amended and Restated: December 2, 2024 |
|---|
| 2024-04-01 | 10-K | 10.27 | Autonomous First Demand Guarantee (Garanzia Autonoma a Prima Richiesta) by and between the Company, EryDel Italy, Inc., EryDel US, Inc., EryDel S.p.A, and the European Investment Bank, dated as of October 20, 2023 |
|---|
| 2024-04-01 | 10-K | 10.26 | Accession, Amendment and Restatement Agreement to the Finance Contract relating to the Finance Contract dated 24 July 2020, as amended from time to time, by and between the Company, EryDel Italy, Inc., EryDel US, Inc., EryDel USA, Inc. EryDel S.p.A, and the European Investment Bank, dated as of October 20, 2023 |
|---|
| 2024-04-01 | 10-K | 10.6 | 2019 Equity Incentive Plan and forms of stock award agreements thereunder |
|---|
| 2023-11-14 | 10-Q | 10.4 | Executive Change in Control and Severance Agreement between Quince Therapeutics, Inc. and Charles Ryan, dated as of September 1, 2023 |
|---|
| 2023-11-14 | 10-Q | 10.3 | Offer Letter between Quince Therapeutics, Inc. and Charles Ryan, dated as of August 1, 2023 |
|---|
| 2023-11-14 | 10-Q | 10.2 | Transition and Separation Agreement between Quince Therapeutics, Inc. and Karen Smith, dated as of August 4, 2023 |
|---|
| 2023-08-03 | 10-Q | 10.1 | Amendment No. 3 to License Agreement dated June 22, 2023 by and between Purdue Research Foundation and Novosteo Inc. |
|---|
| 2023-05-15 | 10-Q | 10.1 | Lighthouse Purchase Agreement |
|---|
| 2022-11-09 | 10-Q | 10.1 | Second Amendment to License Agreement, dated as of July 22, 2022, by and between Purdue Research Foundation and Novosteo, Inc. |
|---|
| 2022-08-09 | 10-Q | 10.19 | Amendment No. 1 to License Agreement dated March 21, 2022 by and between Purdue Research Foundation and Novosteo Inc. |
|---|
| 2022-08-09 | 10-Q | 10.18 | License Agreement dated June 3, 2020, by and between Purdue Research Foundation and Novosteo Inc. |
|---|
| 2022-08-09 | 10-Q | 10.17 | Amended and Restated Outside Director Compensation Policy |
|---|
| 2022-08-09 | 10-Q | 10.16 | Separation Agreement, by and between Cortexyme, Inc. and Leslie Holsinger, dated as of July 31, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.15 | Consent to Sublease, by and between Cortexyme, Inc. and ICON Clinical Research, LLC, dated as of June 8, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.14 | Sublease Agreement, by and between Cortexyme, Inc. and ICON Clinical Research, LLC, dated as of May 5, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.13 | Separation Agreement, by and between Cortexyme, Inc. and Christopher Lowe, dated as of June 10, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.12 | Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Dirk Thye, dated as of May 19, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.11 | Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Karen Smith, dated as of May 19, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.10 | Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Brendan Hannah, dated as of May 19, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.9 | Separation Agreement, by and between Cortexyme, Inc. and Caryn G. McDowell, dated as of May 19, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.4 | Employment Offer Letter, by and between Cortexyme, Inc. and Dirk Thye, dated May 9, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.3 | Employment Offer Letter, by and between Cortexyme, Inc. and Karen Smith, dated May 9, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.2 | Employment Offer Letter, by and between Cortexyme, Inc. and Brendan Hannah, dated May 9, 2022 |
|---|
| 2022-08-09 | 10-Q | 10.1 | Separation Agreement, by and between Cortexyme, Inc. and Michael Detke, dated as of May 2, 2022 |
|---|
| 2022-03-01 | 10-K | 10.2 | Severance Agreement, dated February 1, 2022, between Stephen Dominy and the Registrant |
|---|
| 2022-03-01 | 10-K | 10.1 | Severance Agreement, dated February 1, 2022, between Casey Lynch and the Registrant |
|---|
| 2021-12-23 | 8-K | 10.1 | Open Market Sale AgreementSM dated December 23, 2021, by and between Cortexyme, Inc. and Jefferies LLC. |
|---|
| 2021-10-29 | 10-Q | 10.1 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Ted Monohon, dated as of September 21, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.7 | Third Amendment to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated July 15, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.6 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Stephen S. Dominy, M.D., dated as of May 19, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.5 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Michael Detke, dated as of May 21, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.4 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Leslie Holsinger, dated as of May 18, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.3 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Christopher Lowe, dated as of May 18, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.2 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Caryn McDowell, dated as of May 18, 2021 |
|---|
| 2021-08-06 | 10-Q | 10.1 | Change in Control and Severance Agreement, by and between Cortexyme Inc. and Casey C. Lynch, dated as of May 19, 2021 |
|---|
| 2020-08-14 | 10-Q | 10.3 | Separation Agreement by and between Kristen Gafric and Cortexyme, Inc., dated as of April 27, 2020. |
|---|
| 2020-08-14 | 10-Q | 10.1 | Second Amendment to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated May 26, 2020. |
|---|
| 2020-05-21 | 8-K | 10.1 | Form of Executive Change in Control and Severance Agreement. |
|---|
| 2019-08-09 | 10-Q | 10.1 | Amendment No. 1 to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated April 2, 2019. |
|---|